Table 3 Univariate analysis of PFS
Characteristics | PFS | 95%CI | P-value |
|---|---|---|---|
Gender | 0.446 | ||
Male | 11.70 | 8.245–15.155 | |
Female | 7.4 | 0–17.879 | |
Age(years) | 0.434 | ||
≤ 65 | 12.4 | 1.429–23.371 | |
> 65 | 11.7 | NA | |
ECOG PS | 0.164 | ||
0–1 | 11.7 | 3.745–19.655 | |
2 | 14.7 | NA | |
3 | 7.4 | 0–18.602 | |
Histologic type | 0.166 | ||
Adenocarcinoma | 11.3 | 2.165–18.436 | |
Squamous | 12.4 | 11.280–13.520 | |
Adenosquamous | 4.2 | NA | |
Staging | 0.82 | ||
Stage III | 14.7 | NA | |
Stage IV | 10.3 | 3.722–16.878 | |
Smoking | 0.939 | ||
No | 11.7 | 5.303–18.097 | |
Yes | 10.3 | 2.264–18.336 | |
PD-L1 | 0.048 | ||
Positive | 13.0 | 4.86–21.140 | |
Negative or Unknown | 10.3 | 0–22.39 | |
Metastasis | 0.475 | ||
Yes | 11.7 | 1.489–21.911 | |
No | 10.3 | 1.376–19.224 | |
Metastatic sites at ICI rechallenge initiation | 0.311 | ||
Bone | 7.4 | 0–15.933 | |
Brain | 1.7 | NA | |
Liver | 11.7 | NA | |
Adrenal gland | 2.3 | NA | |
Immune maintenance | 0.962 | ||
Yes | 10.3 | 0–21.751 | |
No | 7.4 | 0–17.141 | |
Rechallenge with the same ICI | 0.776 | ||
Yes | 11.7 | 3.414–19.986 | |
No | 10.3 | 0–22.276 | |
Best overall response to initial ICI therapy | 0.156 | ||
CR/PR | 12.4 | 11.260–13.540 | |
SD/PD | 7.4 | 0–15.612 | |
Initial ICI therapy PFS | 0.304 | ||
> 6 months | 11.7 | 8.822–14.578 | |
≤ 6 months | 4.2 | 0–9.786 | |